US/UK/Canada

Share

Pick a time period -
Tags ( Active)

FIRST SHIPMENT OF IMMULINA DELIVERED TO SCN’S NEW IMMULINA PARTNER AERUS

(NGM: SCN) In accordance to plan SCN has now received and delivered the first order from Aerus, SCN’s new Immulina partner, on totally USD 480 000 with cash payment. Aerus has also committed to purchase Immulina at a value of MSEK 250 during the coming six years in order to maintain the world-wide distribution rights. SCN also expects another order of the same size during this year.As a consequence of this agreement and other actions that have been taken and implemented during the last six months, the SCN management believes that positive cash flow will be shown during the third and

INTERIM REPORT Q2 2009

(NGM:SCN) April-June 2009 in brief for the SCN group • Net sales for the period amounted to MSEK 7.0 • EBIT amounted to MSEK -11.3 • Loss for the period amounted to MSEK -4.8 • Earnings per share, basic and diluted, amounted to SEK -0.31 • New distribution contracts signed for thin400, Immulina and Coldizin, adding new markets in Europe • New Board Member elected: the Norwegian investor Tore Eiklid • Directed share issue decided by the Board increasing equity with 3.7 MSEK January-June 2009 in brief for the SCN group • Net sales for the period amounted to MSEK 18.

REGARDING TRADE IN SCN SHARES ON NGM EQUITY

(NGM: SCN) As previously communicated, Scandinavian Clinical Nutrition AB (SCN) has applied for and been granted de-listing from Oslo Axess in Norway. From September 18 onwards, the SCN share will therefore only be traded on NGM Equity in Sweden, which may bring about certain changes for shareholders whose shares are registered in VPS in Norway.On August 18, 2009, SCN and Oslo Börs communicated that Oslo Börs had decided to approve SCN’s application regarding de-listing from Oslo Axess. The last day of trade on Oslo Axess will be September 17, 2009. From September 18 2009 onwards, trade

SCN SIGNS MAJOR WORLD-WIDE DISTRIBUTION AGREEMENT FOR PATENTED IMMUNE PRODUCT

(NGM: SCN) Scandinavian Clinical Nutrition AB (SCN) through its subsidiary has entered into a wide-ranging marketing and distribution agreement with US-based Aerus, formerly Electrolux North America. The agreement gives the direct sales company of Aerus Holdings, Naturals for Life, the world-wide exclusive rights to sell SCN’s patented immune product Immulina as a food supplement, with exception for markets where SCN already has partners in place.Under the agreement, the Aerus group commits to buying a minimum amount of Immulina well in excess of USD 30 million from SCN’s subsidiary

SCN LEAVES OSLO AXESS

As previously communicated, SCN has applied for de-listing of the company’s shares from the Norwegian Oslo Axess list. On August 17, 2009, Oslo Börs decided to approve the application. The last trading day for the SCN share on Oslo Axess will be September 17, 2009. The listing on NGM Equity remains unchanged.As previously communicated, an extraordinary general meeting in Scandinavian Clinical Nutrition AB (SCN) held on May 20, 2009, decided to apply for de-listing of the company’s shares from Oslo Axess. Oslo Börs has now decided to approve the application and de-list the company’s shares.

FINANCIAL CALENDAR FOR SCN 2009-2010

(NGM:SCN) The Board of Scandinavian Clinical Nutrition i Sverige AB (publ) has decided on the following calendar for 2009-2010: November 13, 2009 Interim Report July-September (Q3, 2009) February 26, 2010 Year-end Report and Interim Report October-December (Q4, 2009) April 22, 2010 Interim Report January-March (Q1, 2010) June 22, 2010 Annual General MeetingFor more information, please contact: Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81 Jörn Erik Aas, Chairman of the Board, jea@scnutrition.com, +47 924 99 360 Scandinavian Clinical Nutrition i Sverige AB (

PUBLICATION OF PROSPECTUS FROM SCN

(NGM:SCN) Today, August 12, 2009, Scandinavian Clinical Nutrition i Sverige AB (publ) publishes a prospectus regarding admission to trading of shares on NGM Equity due to the previously communicated directed share issue and issue of 3,700,000 shares.As previously communicated, at June 30, 2009, the Board of SCN decided to increase the company’s share capital through a directed share issue by virtue of authorization from the 2009 Annual General Meeting. The subscription price was set to SEK 1.00. In the previous release, the share capital increase was erroneously reported as SEK 320,000.

DIRECTED SHARE ISSUE IN SCN TO SETTLE CLAIM FROM LOAN

(NGM:SCN) A consortium of investors have offered Scandinavian Clinical Nutrition AB (SCN) an interest free loan, payable with shares in SCN. The Board of SCN has accepted the offer, and therefore decided to issue a maximum of 3,200,000 shares in SCN at a price of SEK 1 per share to the consortium, by virtue of authorization from the 2009 Annual General Meeting.In accordance with SCN’s previously communicated strategy aiming to strengthen the company’s solidity and financial situation, the Board of SCN has accepted an offer from a consortium of investors regarding an interest free loan.

NORWEGIAN INVESTOR ELECTED NEW MEMBER OF THE BOARD BY THE SCN ANNUAL GENERAL MEETING

(NGM:SCN) At the Annual General Meeting in Scandinavian Clinical Nutrition i Sverige AB (publ) today, the Norwegian investor Tore Eiklid was elected new Member of the Board.“I am very glad to announce that Tore Eiklid has been elected new Member of the Board of SCN. He has extensive experience of the international financial market and a vast network, especially in Norway, and will be a very good complement to the other Board Members. I look forward to continuing as Chairman of the Board for another year, and to seeing the results of our new strategy and all the measures taken to

SCN PLANS TO SELL ADDITIONAL SHARES IN SCANDIVIR

(NGM:SCN) As communicated to the market in previous press releases, for example on March 30, 2009, Scandinavian Clinical Nutrition AB (SCN) has sold parts of the company’s shareholding in Scandivir AB in order to strengthen the company’s financial situation. With reference to the article in the Norwegian financial magazine Finansavisen today, SCN hereby clarifies that the company plans to sell additional parts or all of the company’s shares in Scandivir, in line with the previously communicated strategy.In the previous transactions, Scandivir has been valued to +/- MSEK 100. SCN has good

NOTICE OF ANNUAL GENERAL MEETING

(NGM: SCN) Please be informed that the Annual General Meeting (AGM) of Scandinavian Clinical Nutrition i Sverige AB (publ) (”the Company” or “SCN”) will be held onFriday, June 26, 2009 at 10.00 at Kungsgatan 37, Stockholm, Sweden Attendance at the AGM Shareholders wishing to attend the AGM need to be listed as shareholders in a printed or otherwise presented version of the complete Share Register depicting the conditions on Thursday, June 18, 2009, and to register the intention to attend the meeting with the Company by mail, fax or e-mail no later than 16.00 on Thursday, June 18,

PRESS RELEASE FROM EXTRAORDINARY GENERAL MEETING IN SCANDINAVIAN CLINICAL NUTRITION I SVERIGE AB (PUBL)

(NGM:SCN) Today, May 20, 2009, an Extraordinary General Meeting in Scandinavian Clinical Nutrition AB (SCN) decided to apply for de-listing of the Company’s shares from the Norwegian Oslo Axess list. The listing on the Swedish NGM Equity list however remains unchanged.The Board’s motives for the proposal were in short the following: • the trade in the Company’s shares on Oslo Axess has been very limited • the spread of the shares in Norway is very limited • a double stock exchange listing requires significant resources, both in terms of costs and workload • the Company has

SCN SIGNS STRATEGIC, REGIONAL AGREEMENT FOR COLDIZIN AND IMMULINA IN SOUTH EASTERN EUROPE

(NGM: SCN) Scandinavian Clinical Nutrition AB (SCN) has entered into an exclusive, strategic distribution and supply agreement for the patented products Coldizin and Immulina in South Eastern Europe with a leading company in the Greek health market, Alapis S.A.Under the agreement, Alapis S.A. will exclusively market and distribute Coldizin and Immulina each in eight countries: Greece, Serbia, Bulgaria, Romania, Croatia, Slovenia, Montenegro, Bosnia-Herzegovina, FYRM and Albania. The initial focus will be the launch of both SCN products in Greece and Serbia during Q3 2009, with the other

ANNUAL REPORT SCN 2008

(NGM: SCN)     Scandinavian Clinical Nutrition i Sverige AB (publ) releases the Annual Report for 2008.   From today onwards, the 2008 Annual Report of Scandinavian Clinical Nutrition AB is available on the company’s website www.scnutrition.com. A paper version can be ordered via mail (SCN AB, Stora Nygatan 7, Stockholm), via phone +46 8 586 107 80, via fax +46 8 222 006, or via e-mail info@scnutrition.com.   The Annual General Meeting takes place in Stockholm on June 26, 2009.In comparison with the information presented in the unaudited Year-End and Q4 Report, one

NOTICE OF EXTRAORDINARY GENERAL MEETING IN SCN

(NGM: SCN) The Board of Scandinavian Clinical Nutrition AB (SCN) today decided to propose an Extraordinary General Meeting to apply for de-listing of the company’s shares from Oslo Axess.The Board proposes that the EGM decides to apply to Oslo Börs for de-listing of the Company’s shares from Oslo Axess. No change is however proposed regarding the listing on NGM Equity. The Board’s motives for the proposal are in short the following: • the trade in the Company’s shares on Oslo Axess has been very limited • the spread of the shares in Norway is very limited • a double stock

CLARIFICATION: SHARE ISSUE IN SCN REGISTERED IN MARCH

(NGM:SCN) Through registration of the share issue which was carried out in January at the Swedish Companies Registration Office, the number of shares in Scandinavian Clinical Nutrition AB (SCN) increased with 1,780,000 shares from 16,023,284 to 17,803,284 shares during March, 2009.The company only has one class of shares, and the number of voting rights is therefore the same as the number of shares in the company. This information is published with reference to chapter 4, section 9 in the Swedish Financial Instruments Trading Act. For more information, please contact: Ulf

PRODUCT FROM SCN HAS EFFECT ON THE H1N1 VIRUS

(NGM:SCN) In previous press releases, Scandinavian Clinical Nutrition (SCN) has described positive results from a study where the patented product Immulina has been tested against the influenza virus H1N1, which now has been tied to the swine flu.The study results showed that taking Immulina caused a significant reduction of both clinical symptoms and lung tissue damage after infection by the influenza virus H1N1, the cause of the new swine flu epidemic, compared to placebo. The study was conducted during 2008 at Louisiana State University in USA, and animal studies have also been

SCN EXTENDS UK PARTNERSHIP WITH TWO MORE PRODUCTS

(NGM:SCN) Scandinavian Clinical Nutrition AB (SCN) has extended its collaboration with Vital Life International Ltd by adding two further unique products, thin400 and Immulina, to the product portfolio that will be launched and marketed in the UK, Ireland and the Channel Islands.“I am pleased that we are taking the next step in our business relationship with Vital Life already. In March we agreed on exclusive rights for the cold product Coldizin, and now Vital Life takes the further step on committing to launch the diet product thin400 and the immune system product Immulina. I have high

TERM FOR OFFER TO HOLDERS OF CONVERTIBLE BONDS IN SCN PROLONGED

(NGM:SCN) The Board of Scandinavian Clinical Nutrition AB (SCN) today decided to prolong the term for the offer to holders of convertible bonds in SCN to buy shares in Scandivir until April 24, 2009.On May 12, 2008, an Extraordinary General Meeting (EGM) in SCN decided to issue convertible bonds. On March 31, 2009, an EGM decided to offer the holders of the bonds to transfer their bonds, and the rights attached, to SCN in return for shares in Scandivir AB. The term of the offer was set to April 17, and as per today, subscription forms for a total amount of close to MSEK 19 (out of the

SCN SIGNS LOI FOR SALE OF IMMULINA RIGHTS

(NGM: SCN) Scandinavian Clinical Nutrition AB (SCN) has entered into a Letter of Intent (LOI) with PhytoLab Solutions, Inc. part of the Lifequest group, outlining the intended sale of certain rights to the product Immulina. The LOI also extends the standstill agreement regarding PhytoLab Solutions’ option to acquire the SCN subsidiary containing the rights to Immulina, against a further upfront consideration of USD 1 million.“I am pleased we have reached this first step in the negotiation stage with Lifequest regarding the sale of rights to Immulina. The LOI gives both parties a

SCN INTENDS TO STRENGTHENS FINANCES FURTHER WITH UP TO MSEK 23

Scandinavian Clinical Nutrition AB (SCN) is currently working on several parallel tracks in order to strengthen the company’s financial situation. In addition to the proposed claims settlement which is up for decision at an Extraordinary General Meeting on March 31, the SCN Board intends to sell additional parts of the company’s shares in Scandivir AB, thereby getting additional capital without risking dilution for the shareholders.As previously communicated, SCN has initiated an extensive program designed to reduce the company’s costs and risks compared to previous years. One important

NEW SCN PARTNER TO FUND US MARKETING OF CUUR

(NGM: SCN) Scandinavian Clinical Nutrition AB (SCN) has entered into an agreement with the American company The Neutraceutical Company, LLC (TNC) regarding an advertising campaign for the weight control product CUUR in USA.As recently communicated, SCN has switched strategy regarding marketing in USA and other countries. In accordance with this strategy change, SCN now enters into an agreement where a new, experienced marketing partner assumes the marketing investment and risk for CUUR marketing campaigns. The Neutraceutical Company, LLC (TNC) is a leading American wellness enrichment

CARSTEN WAERN RESIGNS FROM BOARD POSITION IN SCN

(NGM:SCN) Carsten Waern, Member of the Board in Scandinavian Clinical Nutrition AB (SCN), today notified the Board that he wishes to resign from his assignment due to personal reasons.“Leaving my position on the Board of SCN was not an easy decision, especially in these times of financial turbulence in the world, but I feel that it is right, both for the company and myself. I will however remain a major shareholder in the company and follow its progress closely, and I look forward to seeing the outcome of the recently communicated plans decided by the Board to increase the company’s

There are no items matching the current filter
There are no more items matching the current filter
Back to top